(Q38027576)

27 August 2017

title

Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease (English)

1 reference

27 August 2017

3

Dominick J Angiolillo

1 reference

27 August 2017

Fabiana Rollini

1

1 reference

27 August 2017

Antonio Tello-Montoliu

series ordinal

2

1 reference

27 August 2017

publication date

19 July 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

23

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

537-551

1 reference

Platelet function testing in cardiovascular diseases

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Assessing the current role of platelet function testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiogr

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Variability in responsiveness to oral antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Platelet function testing and risk of bleeding complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Bivalirudin for patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Bivalirudin during primary PCI in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Advances in antiplatelet therapy: agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Bleeding associated with current therapies for acute coronary syndrome: what are the mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Assessment of bleeding events in clinical trials--proposal of a new classification

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleedin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Near-patient platelet function testing in patients undergoing coronary artery surgery: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Adenosine diphosphate–induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Diabetes and antiplatelet therapy in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Antithrombotic therapy in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Antithrombotic therapy in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Antiplatelet drug therapy: role of pharmacodynamic and genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

Treatment with Adenosine Diphosphate Receptor Inhibitors—Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.704649

10.3109/09537104.2012.704649

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference